E. Keil

Nonplatinum Topotecan Combinations Versus Topotecan Alone for Recurrent Ovarian Cancer: Results of a Phase III Study of the North-Eastern German Society of Gynecological Oncology Ovarian Cancer Study Group

Jalid Sehouli, Dirk Stengel, Guelten Oskay-Oezcelik et al. · Journal of Clinical Oncology · 2008 · 136 citations · Full text

The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions

Berit Müller, E. Keil, Annika Lehmann et al. · PLoS ONE · 2013 · 74 citations · Full text

Breast Oncology, Clinical Endpoint, Immunology +20

Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO

Jalid Sehouli, Dirk Stengel, Alexander Mustea et al. · Cancer Chemotherapy and Pharmacology · 2007 · 33 citations

Multicenter Phase-ii Study, Medicine, Cancer Management +8

Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)

Jalid Sehouli, Radoslav Chekerov, Alexander Reinthaller et al. · Annals of Oncology · 2016 · 32 citations · Full text

Geico-engot-gcig Intergroup Study, Noggo-ago-study Group-ago Austria, Oncology +8

Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany

Desislava Dimitrova, B Naghavi, Rolf Richter et al. · BMC Cancer · 2021 · 14 citations · Full text